Inclusion Criteria:

- patients with histopathologic diagnosis of well-differentiated neuroendocrine tumour
or carcinoma according to WHO classification

- patients who, according to RECIST criteria (Response Evaluation Criteria in Solid
Tumours) present measurable disease

- patients with progressive disease in the previous 6 months before their inclusion in
the study

- patients with positive IN111 octreotide scintigraphy

Exclusion Criteria:

- patients with surgically removable localised disease

- patients with progressive disease in the first six months of being diagnosed

- patients with intestinal obstruction due to a carcinoid tumour

- patients who have received treatment with somatostatin analogues during the 6 months
before being included in the study

- patients who have received treatment with radiotherapy, chemotherapy or interferon 4
weeks before being included in the study, or planned to receive these during the
study

- patients who have received treatment with liver artery embolisation or
radiopharmaceuticals (endoradiotherapy) 12 weeks before being included in the study,
or planned during the study.